Acquired hemophilia A

References

• Cohen AJ, Kessler CM. Acquired inhibitors. Bailleres Clin Haematol 1996;9:331–354.
   PubMed Web of Science ®Google Scholar
• Morrison AE. Acquired haemophilia and its management. Br J Haematol 1995;89:231–236.
   PubMed Web of Science ®Google Scholar
• Hay CRM. Acquired haemophilia. Bailleres Clin Haematol 1998;11:287–303.
   PubMed Web of Science ®Google Scholar
• Sultan Y. Acquired hemophilia and its treatment. Blood Coagul Fibrinolysis 1997;8(1 Suppl):155–185.
   PubMedGoogle Scholar
• Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001;5:389–404.
   PubMedGoogle Scholar
• Pruthi RK, Nichols WL. Autoimmune factor VIII inhibitors. Curr Opin Hematol 1999;6:314–322.
   PubMedGoogle Scholar
• Hay CRM, Baglin TP, Collins PW, Hill FGH, Keeling DM. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 2000; 111:78–90.
   PubMed Web of Science ®Google Scholar
• Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981;45:200–203.
   PubMed Web of Science ®Google Scholar
• Lottenberg R, Kentro TB, Kitchens CS. Acquired hemo-philia. A natural history study of 16 patients with factor VIII inhibitors receiving little or no therapy. Arch Intern Med 1987;147: 1077–1081.
   PubMed Web of Science ®Google Scholar
• Bossi P, Cabane J, Ninet J, et al. Acquired haemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998;105: 400–408.
   PubMed Web of Science ®Google Scholar
• Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: A single-centre experience over 34 years, 1964-97. Br J Haematol 1999;104:909–914.
   PubMed Web of Science ®Google Scholar
• Yee TT, Taher A, Pasi KJ, Lee CA. A survey of patients with acquired hemophilia in a hemophilia centre over a 28-year period. Clin Lab Haematol 2000;22:275–278.
   PubMedGoogle Scholar
• Di Bona E, Schiavoni M, Castaman G. Acquired hemophilia: Experience of two Italian centres with 17 new cases. Haemophilia 1997;3: 183–188.
   PubMed Web of Science ®Google Scholar
• Morrison AE, Ludlam CA, Kessler C. Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993;81:1513–1520.
   PubMed Web of Science ®Google Scholar
• Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: A multicenter study. Thromb Haemost 1997;78:3–7.
   Web of Science ®Google Scholar
• Delgado J, Yimenez-Yuste V, Hernandez-Navarro F, Villar A. Acquired haemophilia: Review and meta-analysis focused on therapy and prognostic factors. Br J Haematol 2003; 121:21–35.
   PubMed Web of Science ®Google Scholar
• Solymoss S. Postpartum acquired factor VIII inhibitors: Results of a survey. Am J Haematol 1998;59:1–4.
   PubMed Web of Science ®Google Scholar
• Kashyap R, Choudhry VP, Mahapatra M, Chumber S, Saxena R, Kaul HL. Postpartum acquired haemophilia: Clinical recognition and management. Haemophilia 2001;7: 327–330.
   PubMed Web of Science ®Google Scholar
• Mazzucconi MG, Bizzoni L, Giorgi A, et al. Postpartum inhibitor to factor VIII: Treatment with high-dose immuno-globulin and dexamethasone. Haemophilia 2001;7:422–427.
   PubMed Web of Science ®Google Scholar
• Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors: A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995;73:1–5.
   PubMed Web of Science ®Google Scholar
• Kadir RA, Koh MB, Lee CA, Pasi KJ. Acquired haemophilia, an unusual cause of severe postpartum haemorrhage. Br J Obstet Gynaecol 1997;104:854–856.
   PubMedGoogle Scholar
• Baudo F, de Cataldo F. Acquired factor VIII inhibitors in pregnancy: Data from the Italian Haemophilia Register relevant to clinical practice. Br J Obstet Gynaecol 2003;110: 311–314.
   Google Scholar
• Baudo F, de Cataldo F. Acquired factor VIII and IX inhibitors: Survey of the Italian Haemophilia Centers (AICE). Register of acquired factor VIII/IX inhibitors. Haematologica 2002;87:22–28.
   Google Scholar
• Ries M, Wolfel D, Maier-Brandt B. Severe intracranial hemorrhage in a newborn infant with transplacental transfer of an acquired factor VIII:C inhibitor. J Pediatr 1995;127: 649–650.
   PubMed Web of Science ®Google Scholar
• Schulman S, Langevitz P, Livneh A, Martinovitz U, Seligsohn U, Varon D. Cyclosporin therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996;76:344–346.
   PubMed Web of Science ®Google Scholar
• Trotta F, Baiocchi G, La Corte R, Moratelli S, Sun LY. Long-lasting remission and successful treatment of acquired factor VIII inhibitors using cyclophosfamide in a patient with systemic lupus erythematosus. Rheumatology 1999;38: 1007–1009.
   PubMed Web of Science ®Google Scholar
• Soriano RM, Mathews JM, Guerado-Parra E. Acquired haemophilia and rheumatoid arthritis. Br J Rheumatol 1987;26:381–383.
   PubMedGoogle Scholar
• Struillou L, Fiks-Sigaud M, Barrier JH, Blat E. Acquired haemophilia and rheumatoid arthritis: Success of immuno-globulin therapy. J Intern Med 1993;233:304–305.
   PubMed Web of Science ®Google Scholar
• Dannhauser D, Casonato A, Pietrogrande F, et al. Acquired factor VIII:C inhibitor in a patient with Sjögren’s syndrome: Successful treatment with steroid and immunosuppressive therapy. Acta Haematol 1994;91:73–76.
   PubMed Web of Science ®Google Scholar
• Vignes S, Le Moing V, Meekel P, Papo T, Wechsler B, Godeau P. Acquired hemophilia: A rare complication of Sjogren’s syndrome. Clin Exp Rheumatol 1996;14:559–560.
   PubMed Web of Science ®Google Scholar
• Meiklejohn DJ, Watson HG. Acquired haemophilia in association with organ-specific autoimmune disease. Hae-mophilia 2001;7:523–525.
   Google Scholar
• Sievert R, Goldestein ML, Surks MI. Graves’ disease and autoimmune factor VIII deficiency. Thyroid 1996;6: 245–247.
   PubMed Web of Science ®Google Scholar
• Dentale N, Fulgaro C, Guerra L, Fasulo G, Mazzetti M, Fabbri C. Acquisition of factor VIII inhibitor after acute hepatitis C virus infection. Blood 1997;90:3233–3234.
   PubMed Web of Science ®Google Scholar
• O’Reilly RA, Hamilton RD. Acquired haemophilia, menin-gioma and diphenylhydantoin therapy. J Neurosurg 2002;53: 600–605.
   Web of Science ®Google Scholar
• Sallah S, Wan JY. Inhibitors against factor VIII associated with the use of interferon-alpha and fludarabine. Thromb Haemost 2001;86:1119–1121.
   PubMed Web of Science ®Google Scholar
• Regina S, Colombat P, Fimbel B, Guerois C, Gruel Y. Acquired inhibitor to factor VIII in a patient with Hodgkin’s disease following treatment with interferon-alpha. Haemo-philia 2001;7:526–527.
   PubMed Web of Science ®Google Scholar
• Mauser-Bunschoten EP, Damen M, Reesink HW, Roosendal G, Chamuleau RA, van der Berg HM. Formation of antibodies to factor VIII in patients with hemophilia A who are treated with interferon for chronic hepatitis C. Ann Intern Med 1996;125:297–299.
   PubMed Web of Science ®Google Scholar
• Tiplady CW, Hamilton PJ, Galloway MJ. Acquired haemo-philia complicating the remission of a patient with high grade non-Hodgkin’s lymphoma treated by fludarabine. Clin Lab Haem 2000;22:163–165.
   PubMedGoogle Scholar
• Sallah S, Singh P, Hanrahan LR. Antibodies against factor VIII in patients with solid tumors: Successful treatment of cancer may suppress inhibitor formation. Haemostasis 1998;28:244–249.
   PubMedGoogle Scholar
• Hauser I, Lechner K. Solid tumors and factor VIII antibodies. Thromb Haemost 1999;82:1005–1007 .
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Cancer 2001;91:1067–1074.
   PubMed Web of Science ®Google Scholar
• Sohngen D, Specker C, Bach D, et al. Acquired factor VIII inhibitors in nonhemophilic patients. Ann Hematol 1997;74:89–93.
   PubMed Web of Science ®Google Scholar
• Hultin MB. Acquired inhibitors in malignant and nonmalig-nant disease states. Am J Med 1991;91:9–13.
   PubMed Web of Science ®Google Scholar
• Lionnet F, Pulik M, Genet P, Lucas G, Sollet JP. Acquired factor VIII inhibitor associated with a prostate cancer: Simultaneous occurrence and healing. Thromb Haemost 1995;73:327–328.
   PubMed Web of Science ®Google Scholar
• Neilson RF, Walker ID, Roberson M, Factor VIII. inhibitor associated with hepatocellular carcinoma. Clin Lab Haema-tol 1993;15:145–148.
   PubMedGoogle Scholar
• Shurafa M, Raman S, Wollner I. Disappearance of factor VIII antibody after removal of primary colon adenocarcinoma. Am J Hematol 1995;50:149–150.
   PubMed Web of Science ®Google Scholar
• Sallah S, Nguien NP, Abdallah JM, Hanrahan LR. Acquired hemophilia in patients with hematologic malignancies. Arch Pathol Lab Med 2000;124:730–734.
   PubMed Web of Science ®Google Scholar
• Kesley PR, Leyland MJ. Acquired inhibitor to human factor VIII associated with paraproteinemia and subsequent development of chronic lymphocytic leukemia. Br J Med 1982;285:174–176.
   PubMed Web of Science ®Google Scholar
• Kazmi MA, Pickering W, Smith MP, Holland LJ, Savidge GF. Acquired haemophilia A: Errors in the diagnosis. Blood Coagul Fibrinolysis 1998;9:623–628.
   PubMed Web of Science ®Google Scholar
• Taher A, Abiad R, Uthman I. Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance. Lupus 2003;12:854–856.
   PubMed Web of Science ®Google Scholar
• Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunshoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: Improved specificity and reliability. Thromb Haemost 1995;73: 247.
   PubMed Web of Science ®Google Scholar
• Scandella D, Nakai H, Felch M, et al. In hemophilia A and autoantibody inhibitor patients: The factor VIII A2 domain and light chain are most immunogenic. Thromb Res 2001;101:377–385.
   PubMed Web of Science ®Google Scholar
• Green D, Blanc J, Foiles N. Spontaneous inhibitors of factor VIII: Kinetics of inactivation of human and porcine factor VIII. J Lab Clin Med 1999;133:260–264.
   PubMed Web of Science ®Google Scholar
• Delgado J, Villar A, Jimenez-Yuste V, Gago J, Quintana M, Hernandez-Navarro F. Acquired hemophilia: A single-center survey with emphasis on immunotherapy and treatment-related side-effects. Eur J Haematol 2002;69:158–164.
   PubMed Web of Science ®Google Scholar
• Ludlam CA, Morrison AE, Kessler C. Treatment of acquired hemophilia. Semin Hematol 1994;31:16–19.
   PubMed Web of Science ®Google Scholar
• Shapiro A. Inhibitor treatment: State of the art. Semin Hematol 2001;38:26–34.
   PubMed Web of Science ®Google Scholar
• Kessler CM. Acquired factor VIII autoantibody inhibitors: Current concept and potential therapeutic strategies for the future. Haematologica 2000;85( Suppl.):57–63.
   PubMedGoogle Scholar
• Ingerslev J. Strategies for the treatment of inhibitor patients. Haematologica 2000;85:15–20.
   PubMedGoogle Scholar
• Mudad R, Kane WH. DDAVP in acquired haemophilia A: Case report and review of the literature. Am J Hematol 1993;43:295–299.
   PubMed Web of Science ®Google Scholar
• Gandini G, Franchini M, Manzato F, Lippi G, Aprili G. A successful combination of prednisone, high-dose intra-venous immunoglobulin and desmopressin in the treatment of acquired haemophilia A with high-titer inhibitor. Haematologica 1999;84:1054.
   PubMed Web of Science ®Google Scholar
• Kessler CM, Ludlam CA. The treatment of acquired factor VIII inhibitors: World-wide experience with porcine factor VIII concentrate. Semin Hematol 1993;30:22–27.
   PubMed Web of Science ®Google Scholar
• Hay CR, Bolton-Maggs P. Porcine factor VIIIC in the management of patients with factor VIII inhibitors. Trans Med Rev 1991;5:145–151.
   Google Scholar
• Charles RMH. Porcine factor VIII: Past, present and future. Haematologica 2000;85( Suppl):21–25.
   PubMedGoogle Scholar
• Sjamsoedin LJM, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. N Engl J Med 1981;305:717–721.
   PubMed Web of Science ®Google Scholar
• Hilgartner MW, Knatterud GL. Feiba Study Group. The use of factor eight inhibitor by-passing activity (FEIBA Immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983;61:36–40.
   PubMed Web of Science ®Google Scholar
• Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophy-lactic therapy in haemophilia patients with inhibitors. Haemophilia 1999;5 (supp1.3):25–32.
   PubMedGoogle Scholar
• Hedner U, Glazer S, Falch J. Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfus Med Rev 1993;7:78–83.
   PubMedGoogle Scholar
• Roberts HR. The use of agents that by-pass factor VIII inhibitors in patients with hemophilia. Vox Sang 1999;77 (suppl. 1):38–41.
   PubMedGoogle Scholar
• Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002;42:114–124.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Chediak J, Fink KI, Galvez AG, Shah PC, Sham RL. Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII. Am J Hematol 2000;63:109–113.
   PubMed Web of Science ®Google Scholar
• Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicenter study. Throm Haemost 1997;78: 1463–1467.
   PubMed Web of Science ®Google Scholar
• Franchini M, Capra F, Capelli C, de Maria E, Lippi G, Gandini G. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer. Haematologica 2001;86:E12.
   PubMedGoogle Scholar
• Papadaki HA, Xylouri I, Valatas W, Petinarakis J, Konto-poulou I, Eliopoulos GD. Severe acquired hemophilia A successfully treated with activated recombinant human factor VII. Ann Hematol 1997;77:123–125.
   Web of Science ®Google Scholar
• Siddiqui MAA, Scott U. Recombinant factor VIIa (eptacog alfa): A review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs 2005; 65:1161–1177.
   PubMed Web of Science ®Google Scholar
• Baudo F, de Cataldo F, Gaidano G. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: Data from the Italian registry of acquired hemophilia. Haematologica 2004;88:759–761.
   Google Scholar
• Green D. Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 1971;37:381–387.
   PubMed Web of Science ®Google Scholar
• Spero JA, Lewis JH, Hasiba U. Corticosteroid therapy for acquired F VIII:C inhibitors. Br J Haematol 1981;48: 635–642.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, Phillips MD. Successful treatment of acquired hemophilia with oral immunosuppressive therapy. Ann Intern Med 1997;127:206–209.
   PubMed Web of Science ®Google Scholar
• Lian EC, Larcada AF, Chiu AY. Combination immuno-suppressive therapy after factor VIII infusion for acquired factor VIII inhibitor. Ann Intern Med 1989;110:774–778.
   PubMed Web of Science ®Google Scholar
• Green D, Rademaker AW, Briet E. A prospective, random-ized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993;70:753–757.
   PubMed Web of Science ®Google Scholar
• Schwartz RS, Gabriel DA, Aledort LM, Green D, Kessler CM. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intra-venous gammaglobulin. Blood 1995;86:797–804.
   PubMed Web of Science ®Google Scholar
• Schulman S, Langevitz P, Livneh U, Mortinovitz U, Seligsohn U, Varon D. Cyclosporine therapy for acquired factor VIII inhibitor in a patient with systemic lupus erythematosus. Thromb Haemost 1996;76:344–346.
   PubMed Web of Science ®Google Scholar
• Petrovic M, Derom E, Baele G. Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haemato-logica 2000;85:895–896.
   PubMed Web of Science ®Google Scholar
• Ali R, Ozcelik T, Ozkalemkas F, et al. Successful treatment of acquired haemophilia with prednisolone therapy. Haemo-philia 2003;9:741–743.
   PubMed Web of Science ®Google Scholar
• Francesconi M, Korninger C, Thaler E, Niessner H, Höcker P, Lechner K. Plasmapheresis: Its value in the management of patients with antibodies to factor VIII. Haemostasis 1982;11:79–85.
   PubMedGoogle Scholar
• Jansen M, Schmaldienst S, Banyai S, Quehenberger P, Pabinger I, Derfler K. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 2001;112:91–97.
   PubMed Web of Science ®Google Scholar
• Guillet B, Kriaa F, Huisse MG, Proulle V, George C, Tchernia G. Protein A sepharose immunoadsorption: Immunological and haemostatic effects in two cases of acquired haemophilia. Br J Haematol 2001;114:837–844.
   PubMed Web of Science ®Google Scholar
• Ogata H, Sakai S, Koiwa F, et al. Plasma exchange for acquired hemophilia: A case report. Ther Apher 1999;3: 320–322.
   PubMedGoogle Scholar
• Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gamma-globulin. Lancet 1984;2:765–768.
   PubMed Web of Science ®Google Scholar
• Crenier L, Ducobu J, des Grottes JM, Cerny J, Delaunoit C, Capel P. Low response to high-dose intravenous immuno-globulin in the treatment of acquired factor VIII inhibitor. Br J Haematol 1996;95:750–753.
   PubMed Web of Science ®Google Scholar
• Brox AG, Laryea H, Pelletier M. Successful treatment of acquired factor VIII inhibitors with cyclosporin. Am J Hematol 1998;57:87–88.
   PubMed Web of Science ®Google Scholar
• Maclean PS, Tait RC, Lowe GD, Walker ID, McColl MD. Successful elimination of factor VIII inhibitor using cyclosporin A. Br J Haematol 2003;122:1024–1025.
   PubMed Web of Science ®Google Scholar
• Au WY, Lam CC, Kwong YL. Successful treatment of acquired factor VIII inhibitor with cyclosporin. Haemophilia 2004;10:98–100.
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY. Efficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophi-lia. Blood 2003;101:943–945.
   PubMed Web of Science ®Google Scholar
• Schwedtfeger R, Hintz G, Huhn G. Successful treatment of a patient with postpartum factor VIII inhibitors with recombi-nant human interferon alpha-2a. Am J Hematol 1991;45: 190–193.
   Web of Science ®Google Scholar
• Kain S, Copeland TS, Leahy ME. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (ritux-imab). Br J Haematol 2002;119: 578.
   PubMed Web of Science ®Google Scholar
• Wiestner A, Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitor. Blood 2002;100:3426–3428.
   PubMed Web of Science ®Google Scholar
• Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004;103:4424–4428.
   PubMed Web of Science ®Google Scholar
• Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia. Haematologica 2000; 85:64–68.
   PubMedGoogle Scholar
• Kazatchkine MD, Lacroix-Desmazes S, Moreau A, Kaveri SV. Idiotypic regulation of anti-factor VIII antibodies. Haematologica 2000;85:97–99.
   PubMedGoogle Scholar
• von Depka M. Immune tolerance therapy in patients with acquired hemophilia. Hematology 2004;9:245–257.
   PubMedGoogle Scholar
• Huth-Kuhne A, Ehrenforth S, Scharrer I, Zimmermann R. A new theraputic protocol for a rapid FVIII inhibitor elimination in acquired hemophilia. Blood 2000;96:abs 268a.
   Web of Science ®Google Scholar